Trinity Biotech PLC (NASDAQ:TRIB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “

Separately, Stephens downgraded shares of Trinity Biotech PLC from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, October 5th.

Trinity Biotech PLC (NASDAQ:TRIB) opened at 6.80 on Friday. Trinity Biotech PLC has a 52-week low of $5.76 and a 52-week high of $13.68. The company’s 50 day moving average is $0.00 and its 200-day moving average is $0.00.

Trinity Biotech PLC (NASDAQ:TRIB) last announced its earnings results on Tuesday, October 25th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $26.10 million for the quarter, compared to the consensus estimate of $26.50 million. Trinity Biotech PLC had a net margin of 3.04% and a return on equity of 2.73%. Equities research analysts expect that Trinity Biotech PLC will post ($1.67) earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Trinity Biotech PLC by 5.1% in the third quarter. JPMorgan Chase & Co. now owns 8,253 shares of the company’s stock valued at $109,000 after buying an additional 400 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in Trinity Biotech PLC during the third quarter valued at approximately $170,000. Morgan Stanley increased its position in Trinity Biotech PLC by 4.5% in the third quarter. Morgan Stanley now owns 15,345 shares of the company’s stock valued at $202,000 after buying an additional 663 shares during the period. Raymond James & Associates increased its position in Trinity Biotech PLC by 5.3% in the second quarter. Raymond James & Associates now owns 29,823 shares of the company’s stock valued at $338,000 after buying an additional 1,489 shares during the period. Finally, State Street Corp increased its position in Trinity Biotech PLC by 100.7% in the second quarter. State Street Corp now owns 34,953 shares of the company’s stock valued at $396,000 after buying an additional 17,539 shares during the period. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Receive News & Stock Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related stocks with our FREE daily email newsletter.